Trial reportBMC anesthesiology2026
Analgesic efficacy of liposomal bupivacaine adductor canal block combined with periarticular infiltration after total knee arthroplasty: a prospective, double-blind, randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposomal Bupivacaine in Perioperative Analgesia: A Comprehensive Review of Clinical Efficacy, Safety, and Economic Context.Current pain and headache reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative pain after total knee arthroplasty remains substantial despite multimodal analgesia (MMA); however, whether adding liposomal bupivacaine provides clinically meaningful benefits over conventional long-acting local anesthetics within contemporary regional anesthesia–based pathways remains unclear.
methodsIn this single-center, double-blind, randomized controlled trial, 72 patients undergoing unilateral primary TKA were randomized into three groups: levobupivacaine alone (ZB), liposomal bupivacaine alone (LB), and a combination of liposomal bupivacaine and levobupivacaine (LZB). All patients received a standardized MMA protocol including an adductor canal block (ACB) and a periarticular injection (PAI). Primary outcomes were postoperative pain intensity at rest and during activity, measured by the Visual Analogue Scale (VAS). Secondary outcomes included knee range of motion (ROM), patient-controlled intravenous analgesia (PCA) utilization, sensory disturbances within the saphenous nerve distribution, postoperative complication rates, length of hospital stay, and patient satisfaction.
resultsAmong the 62 patients who completed the study, resting pain scores showed no significant differences between groups. However, activity-related pain scores were significantly lower in the LB and LZB groups than in the ZB group between 36 and 72 h postoperatively (p < 0.05). Additionally, the time to first PCA request was significantly longer in the LB and LZB groups than in the ZB group. The LB group exhibited a higher incidence of sensory disturbances in the saphenous nerve distribution than the ZB group at 48 and 72 h postoperatively (p < 0.05). No significant differences emerged regarding ROM, opioid consumption, complication rates, length of hospital stay, or patient satisfaction.
conclusionsIn patients undergoing total knee arthroplasty, incorporating liposomal bupivacaine into an analgesic regimen involving adductor canal block and periarticular infiltration provides prolonged analgesia and superior control of activity-related pain. This may facilitate early postoperative mobilization, thereby promoting early recovery. These findings support the potential of this approach in accelerating the recovery process.
trial registrationThis study was prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2400084619) on May 21, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.